The Use of B-Type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants

This study has been completed.

First Received: July 10, 2007 No Changes Posted

Sponsor:	University of Virginia
Information provided by:	University of Virginia
ClinicalTrials.gov Identifier:	NCT00500305

Purpose

A patent ductus arteriosus (PDA) is associated with increased morbidity in premature infants. Standard indomethacin treatment is associated with intestinal and renal morbidity. B-type natriuretic peptide is elevated in significant PDAs. This study will determine whether BNP guided therapy could reduce doses of indomethacin.

Condition	Intervention
Indomethacin Therapy Patent Ductus Arteriosus	Procedure: Withhold standard INDO dose if BNP < 100 pg/ml

Study Type:	Interventional
Study Design:	Diagnostic, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by University of Virginia:

Primary Outcome Measures:

Number of indomethacin doses given on study [ Time Frame: 2 days ]

Secondary Outcome Measures:

rate of PDA ligation [ Time Frame: Discharge from NICU ]
Rate of Chronic lung disease [ Time Frame: 36 weeks corrected gestational age ]

Enrollment:	60
Study Start Date:	April 2004
Study Completion Date:	March 2007

Eligibility

Ages Eligible for Study:	up to 4 Months
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Infants with echocardiographically confirmed PDA
Infants determined by attending physician to require PDA closure

Exclusion Criteria:

infants with congenital hearts disease
infants with creatinine value > 2.0

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00500305

Sponsors and Collaborators

University of Virginia

Investigators

Principal Investigator:

D Sc Lim, MD

University of Virginia

More Information

No publications provided

Study ID Numbers:	HIC# 10946
Study First Received:	July 10, 2007
Last Updated:	July 10, 2007
ClinicalTrials.gov Identifier:	NCT00500305 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Virginia:

indomethacin therapy
patent ductus arteriosus

Additional relevant MeSH terms:

Natriuretic Peptide, Brain
Heart Diseases
Cardiovascular Abnormalities
Natriuretic Agents
Therapeutic Uses
Physiological Effects of Drugs

Cardiovascular Diseases
Cardiovascular Agents
Congenital Abnormalities
Heart Defects, Congenital
Pharmacologic Actions
Ductus Arteriosus, Patent

ClinicalTrials.gov processed this record on February 08, 2010